A new trading day began on Friday, with Regenxbio Inc (NASDAQ: RGNX) stock price up 7.94% from the previous day of trading, before settling in for the closing price of $12.85. RGNX’s price has ranged from $5.03 to $13.99 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -12.18% over the past five years. Meanwhile, its annual earnings per share averaged 32.89%. With a float of $46.14 million, this company’s outstanding shares have now reached $50.62 million.
Regenxbio Inc (RGNX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 8.88%, while institutional ownership is 81.44%. The most recent insider transaction that took place on Oct 09 ’25, was worth 262,635. In this transaction Chief Executive Officer of this company sold 20,811 shares at a rate of $12.62, taking the stock ownership to the 216,162 shares. Before that another transaction happened on Oct 09 ’25, when Company’s Director proposed sale 20,811 for $12.22, making the entire transaction worth $254,310.
Regenxbio Inc (RGNX) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -1.01 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.49% during the next five years compared to -12.18% drop over the previous five years of trading.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Here are Regenxbio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.66. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.49, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -1.74 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Regenxbio Inc (NASDAQ: RGNX) saw its 5-day average volume 0.59 million, a negative change from its year-to-date volume of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 58.80%.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 94.63%, which indicates a significant increase from 84.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.84 in the past 14 days, which was higher than the 0.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.15, while its 200-day Moving Average is $9.35. Nevertheless, the first resistance level for the watch stands at $14.51 in the near term. At $15.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.06. If the price goes on to break the first support level at $12.96, it is likely to go to the next support level at $12.05. The third support level lies at $11.41 if the price breaches the second support level.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
With a market capitalization of 702.14 million, the company has a total of 50,623K Shares Outstanding. Currently, annual sales are 83,330 K while annual income is -227,100 K. The company’s previous quarter sales were 29,730 K while its latest quarter income was -61,940 K.
